Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: A prospective, randomized, open-label, placebo-controlled pilot study
Objective: This study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for Candida prophylaxis in very low birth weight (VLBW) neonates. Methods: This prospective, randomized, open-label, placebo-controlled study included neonates who were <32 weeks’ gestational age, <7 d...
Saved in:
| Published in | Clinical therapeutics Vol. 32; no. 2; pp. 265 - 271 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Bridgewater, NJ
EM Inc USA
01.02.2010
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0149-2918 1879-114X 1879-114X |
| DOI | 10.1016/j.clinthera.2010.02.016 |
Cover
| Abstract | Objective: This study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for
Candida prophylaxis in very low birth weight (VLBW) neonates.
Methods: This prospective, randomized, open-label, placebo-controlled study included neonates who were <32 weeks’ gestational age, <7 days old, and weighing <1500 g at birth. Subjects were randomized to receive L-AmB 5 mg/kg per week or placebo (dextrose water) and were followed until 6 weeks of age. Surveillance cultures were obtained at baseline, at 72 hours, and weekly thereafter. Study drug was continued until 6 weeks after birth or the discontinuation of high-risk treatments and invasive devices, whichever occurred first. Blood cultures were obtained as clinically indicated. The primary end point was development of
Candida colonization by 6 weeks’ postnatal age; secondary end points included development of invasive candidiasis and occurrence of treatment-related adverse events. Safety variables included renal and hepatic function tests, incidence of grade III–IV intraventricular hemorrhage (IVH) and necrotizing enterocolitis (NEC), and mortality.
Results: Forty subjects were enrolled and randomized to receive L-AmB (12 males, 8 females; 50% white) or placebo (12 males, 8 females; 35% white). Subjects were evenly distributed by gestational age, age at enrollment, birth weight, race, and sex. Consent was withdrawn after completion of study treatment in 1 subject (L-AmB); 1 subject in each study arm died during the study; and 3 subjects were transferred back to their referring institutions (1 L-AmB, 2 placebo). Thus, 17 subjects in each arm completed all study procedures, although all 40 subjects were evaluable. Colonization before administration of study drug was noted in 4 L-AmB subjects (20%) and 1 placebo subject (5%); 1 (5%) and 3 (15%) subjects in the respective groups developed colonization while receiving study drug. No L-AmB subjects and 1 placebo subject developed candidiasis. One subject in each group died; these deaths were not considered related to study drug or fungal infection. There were no clinical differences between groups in the incidence of grade III–IV IVH, NEC, hypokalemia, nephrotoxicity, need for platelet or packed red blood cell transfusion, or mortality.
Conclusions: L-AmB 5 mg/kg once weekly was generally well tolerated in these VLBW infants. The data did not allow evaluation of efficacy. A larger, multicenter, randomized clinical trial of L-AmB for
Candida prophylaxis that is appropriately powered is warranted. |
|---|---|
| AbstractList | Abstract Objective: This study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for Candida prophylaxis in very low birth weight (VLBW) neonates. Methods: This prospective, randomized, open-label, placebo-controlled study included neonates who were <32 weeks’ gestational age, <7 days old, and weighing <1500 g at birth. Subjects were randomized to receive L-AmB 5 mg/kg per week or placebo (dextrose water) and were followed until 6 weeks of age. Surveillance cultures were obtained at baseline, at 72 hours, and weekly thereafter. Study drug was continued until 6 weeks after birth or the discontinuation of high-risk treatments and invasive devices, whichever occurred first. Blood cultures were obtained as clinically indicated. The primary end point was development of Candida colonization by 6 weeks’ postnatal age; secondary end points included development of invasive candidiasis and occurrence of treatment-related adverse events. Safety variables included renal and hepatic function tests, incidence of grade III–IV intraventricular hemorrhage (IVH) and necrotizing enterocolitis (NEC), and mortality. Results: Forty subjects were enrolled and randomized to receive L-AmB (12 males, 8 females; 50% white) or placebo (12 males, 8 females; 35% white). Subjects were evenly distributed by gestational age, age at enrollment, birth weight, race, and sex. Consent was withdrawn after completion of study treatment in 1 subject (L-AmB); 1 subject in each study arm died during the study; and 3 subjects were transferred back to their referring institutions (1 L-AmB, 2 placebo). Thus, 17 subjects in each arm completed all study procedures, although all 40 subjects were evaluable. Colonization before administration of study drug was noted in 4 L-AmB subjects (20%) and 1 placebo subject (5%); 1 (5%) and 3 (15%) subjects in the respective groups developed colonization while receiving study drug. No L-AmB subjects and 1 placebo subject developed candidiasis. One subject in each group died; these deaths were not considered related to study drug or fungal infection. There were no clinical differences between groups in the incidence of grade III–IV IVH, NEC, hypokalemia, nephrotoxicity, need for platelet or packed red blood cell transfusion, or mortality. Conclusions: L-AmB 5 mg/kg once weekly was generally well tolerated in these VLBW infants. The data did not allow evaluation of efficacy. A larger, multicenter, randomized clinical trial of L-AmB for Candida prophylaxis that is appropriately powered is warranted. Objective_ This study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for Candida prophylaxis in very low birth weight (VLBW) neonates. Methods_ This prospective, randomized, open-label, placebo-controlled study included neonates who were <32 weeks' gestational age, <7 days old, and weighing <1500 g at birth. Subjects were randomized to receive L-AmB 5 mg/kg per week or placebo (dextrose water) and were followed until 6 weeks of age. Surveillance cultures were obtained at baseline, at 72 hours, and weekly thereafter. Study drug was continued until 6 weeks after birth or the discontinuation of high-risk treatments and invasive devices, whichever occurred first. Blood cultures were obtained as clinically indicated. The primary end point was development of Candida colonization by 6 weeks' postnatal age; secondary end points included development of invasive candidiasis and occurrence of treatment-related adverse events. Safety variables included renal and hepatic function tests, incidence of grade III-IV intraventricular hemorrhage (IVH) and necrotizing enterocolitis (NEC), and mortality. Results_ Forty subjects were enrolled and randomized to receive L-AmB (12 males, 8 females; 50% white) or placebo (12 males, 8 females; 35% white). Subjects were evenly distributed by gestational age, age at enrollment, birth weight, race, and sex. Consent was withdrawn after completion of study treatment in 1 subject (L-AmB); 1 subject in each study arm died during the study; and 3 subjects were transferred back to their referring institutions (1 L-AmB, 2 placebo). Thus, 17 subjects in each arm completed all study procedures, although all 40 subjects were evaluable. Colonization before administration of study drug was noted in 4 L-AmB subjects (20%) and 1 placebo subject (5%); 1 (5%) and 3 (15%) subjects in the respective groups developed colonization while receiving study drug. No L-AmB subjects and 1 placebo subject developed candidiasis. One subject in each group died; these deaths were not considered related to study drug or fungal infection. There were no clinical differences between groups in the incidence of grade III-IV IVH, NEC, hypokalemia, nephrotoxicity, need for platelet or packed red blood cell transfusion, or mortality. Conclusions_ L-AmB 5 mg/kg once weekly was generally well tolerated in these VLBW infants. The data did not allow evaluation of efficacy. A larger, multicenter, randomized clinical trial of L-AmB for Candida prophylaxis that is appropriately powered is warranted. This study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for Candida prophylaxis in very low birth weight (VLBW) neonates. This prospective, randomized, open-label, placebo-controlled study included neonates who were <32 weeks' gestational age, <7 days old, and weighing <1500 g at birth. Subjects were randomized to receive L-AmB 5 mg/kg per week or placebo (dextrose water) and were followed until 6 weeks of age. Surveillance cultures were obtained at baseline, at 72 hours, and weekly thereafter. Study drug was continued until 6 weeks after birth or the discontinuation of high-risk treatments and invasive devices, whichever occurred first. Blood cultures were obtained as clinically indicated. The primary end point was development of Candida colonization by 6 weeks' postnatal age; secondary end points included development of invasive candidiasis and occurrence of treatment-related adverse events. Safety variables included renal and hepatic function tests, incidence of grade III-IV intraventricular hemorrhage (IVH) and necrotizing enterocolitis (NEC), and mortality. Forty subjects were enrolled and randomized to receive L-AmB (12 males, 8 females; 50% white) or placebo (12 males, 8 females; 35% white). Subjects were evenly distributed by gestational age, age at enrollment, birth weight, race, and sex. Consent was withdrawn after completion of study treatment in 1 subject (L-AmB); 1 subject in each study arm died during the study; and 3 subjects were transferred back to their referring institutions (1 L-AmB, 2 placebo). Thus, 17 subjects in each arm completed all study procedures, although all 40 subjects were evaluable. Colonization before administration of study drug was noted in 4 L-AmB subjects (20%) and 1 placebo subject (5%); 1 (5%) and 3 (15%) subjects in the respective groups developed colonization while receiving study drug. No L-AmB subjects and 1 placebo subject developed candidiasis. One subject in each group died; these deaths were not considered related to study drug or fungal infection. There were no clinical differences between groups in the incidence of grade III-IV IVH, NEC, hypokalemia, nephrotoxicity, need for platelet or packed red blood cell transfusion, or mortality. L-AmB 5 mg/kg once weekly was generally well tolerated in these VLBW infants. The data did not allow evaluation of efficacy. A larger, multicenter, randomized clinical trial of L-AmB for Candida prophylaxis that is appropriately powered is warranted. Objective: This study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for Candida prophylaxis in very low birth weight (VLBW) neonates. Methods: This prospective, randomized, open-label, placebo-controlled study included neonates who were <32 weeks’ gestational age, <7 days old, and weighing <1500 g at birth. Subjects were randomized to receive L-AmB 5 mg/kg per week or placebo (dextrose water) and were followed until 6 weeks of age. Surveillance cultures were obtained at baseline, at 72 hours, and weekly thereafter. Study drug was continued until 6 weeks after birth or the discontinuation of high-risk treatments and invasive devices, whichever occurred first. Blood cultures were obtained as clinically indicated. The primary end point was development of Candida colonization by 6 weeks’ postnatal age; secondary end points included development of invasive candidiasis and occurrence of treatment-related adverse events. Safety variables included renal and hepatic function tests, incidence of grade III–IV intraventricular hemorrhage (IVH) and necrotizing enterocolitis (NEC), and mortality. Results: Forty subjects were enrolled and randomized to receive L-AmB (12 males, 8 females; 50% white) or placebo (12 males, 8 females; 35% white). Subjects were evenly distributed by gestational age, age at enrollment, birth weight, race, and sex. Consent was withdrawn after completion of study treatment in 1 subject (L-AmB); 1 subject in each study arm died during the study; and 3 subjects were transferred back to their referring institutions (1 L-AmB, 2 placebo). Thus, 17 subjects in each arm completed all study procedures, although all 40 subjects were evaluable. Colonization before administration of study drug was noted in 4 L-AmB subjects (20%) and 1 placebo subject (5%); 1 (5%) and 3 (15%) subjects in the respective groups developed colonization while receiving study drug. No L-AmB subjects and 1 placebo subject developed candidiasis. One subject in each group died; these deaths were not considered related to study drug or fungal infection. There were no clinical differences between groups in the incidence of grade III–IV IVH, NEC, hypokalemia, nephrotoxicity, need for platelet or packed red blood cell transfusion, or mortality. Conclusions: L-AmB 5 mg/kg once weekly was generally well tolerated in these VLBW infants. The data did not allow evaluation of efficacy. A larger, multicenter, randomized clinical trial of L-AmB for Candida prophylaxis that is appropriately powered is warranted. This study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for Candida prophylaxis in very low birth weight (VLBW) neonates.OBJECTIVEThis study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for Candida prophylaxis in very low birth weight (VLBW) neonates.This prospective, randomized, open-label, placebo-controlled study included neonates who were <32 weeks' gestational age, <7 days old, and weighing <1500 g at birth. Subjects were randomized to receive L-AmB 5 mg/kg per week or placebo (dextrose water) and were followed until 6 weeks of age. Surveillance cultures were obtained at baseline, at 72 hours, and weekly thereafter. Study drug was continued until 6 weeks after birth or the discontinuation of high-risk treatments and invasive devices, whichever occurred first. Blood cultures were obtained as clinically indicated. The primary end point was development of Candida colonization by 6 weeks' postnatal age; secondary end points included development of invasive candidiasis and occurrence of treatment-related adverse events. Safety variables included renal and hepatic function tests, incidence of grade III-IV intraventricular hemorrhage (IVH) and necrotizing enterocolitis (NEC), and mortality.METHODSThis prospective, randomized, open-label, placebo-controlled study included neonates who were <32 weeks' gestational age, <7 days old, and weighing <1500 g at birth. Subjects were randomized to receive L-AmB 5 mg/kg per week or placebo (dextrose water) and were followed until 6 weeks of age. Surveillance cultures were obtained at baseline, at 72 hours, and weekly thereafter. Study drug was continued until 6 weeks after birth or the discontinuation of high-risk treatments and invasive devices, whichever occurred first. Blood cultures were obtained as clinically indicated. The primary end point was development of Candida colonization by 6 weeks' postnatal age; secondary end points included development of invasive candidiasis and occurrence of treatment-related adverse events. Safety variables included renal and hepatic function tests, incidence of grade III-IV intraventricular hemorrhage (IVH) and necrotizing enterocolitis (NEC), and mortality.Forty subjects were enrolled and randomized to receive L-AmB (12 males, 8 females; 50% white) or placebo (12 males, 8 females; 35% white). Subjects were evenly distributed by gestational age, age at enrollment, birth weight, race, and sex. Consent was withdrawn after completion of study treatment in 1 subject (L-AmB); 1 subject in each study arm died during the study; and 3 subjects were transferred back to their referring institutions (1 L-AmB, 2 placebo). Thus, 17 subjects in each arm completed all study procedures, although all 40 subjects were evaluable. Colonization before administration of study drug was noted in 4 L-AmB subjects (20%) and 1 placebo subject (5%); 1 (5%) and 3 (15%) subjects in the respective groups developed colonization while receiving study drug. No L-AmB subjects and 1 placebo subject developed candidiasis. One subject in each group died; these deaths were not considered related to study drug or fungal infection. There were no clinical differences between groups in the incidence of grade III-IV IVH, NEC, hypokalemia, nephrotoxicity, need for platelet or packed red blood cell transfusion, or mortality.RESULTSForty subjects were enrolled and randomized to receive L-AmB (12 males, 8 females; 50% white) or placebo (12 males, 8 females; 35% white). Subjects were evenly distributed by gestational age, age at enrollment, birth weight, race, and sex. Consent was withdrawn after completion of study treatment in 1 subject (L-AmB); 1 subject in each study arm died during the study; and 3 subjects were transferred back to their referring institutions (1 L-AmB, 2 placebo). Thus, 17 subjects in each arm completed all study procedures, although all 40 subjects were evaluable. Colonization before administration of study drug was noted in 4 L-AmB subjects (20%) and 1 placebo subject (5%); 1 (5%) and 3 (15%) subjects in the respective groups developed colonization while receiving study drug. No L-AmB subjects and 1 placebo subject developed candidiasis. One subject in each group died; these deaths were not considered related to study drug or fungal infection. There were no clinical differences between groups in the incidence of grade III-IV IVH, NEC, hypokalemia, nephrotoxicity, need for platelet or packed red blood cell transfusion, or mortality.L-AmB 5 mg/kg once weekly was generally well tolerated in these VLBW infants. The data did not allow evaluation of efficacy. A larger, multicenter, randomized clinical trial of L-AmB for Candida prophylaxis that is appropriately powered is warranted.CONCLUSIONSL-AmB 5 mg/kg once weekly was generally well tolerated in these VLBW infants. The data did not allow evaluation of efficacy. A larger, multicenter, randomized clinical trial of L-AmB for Candida prophylaxis that is appropriately powered is warranted. |
| Author | Singh, Jasjit Shea, Kathy Vargas-Shiraishi, Ofelia M. Ashouri, Negar Dhar, Vijay Morris, Mindy Cleary, John P. Arrieta, Antonio C. Kukreja, Sudeep |
| Author_xml | – sequence: 1 givenname: Antonio C. surname: Arrieta fullname: Arrieta, Antonio C. email: aarrieta@choc.org organization: Division of Pediatric Infectious Diseases, Children’s Hospital of Orange County, Orange, California – sequence: 2 givenname: Kathy surname: Shea fullname: Shea, Kathy organization: Division of Pediatric Infectious Diseases, Children’s Hospital of Orange County, Orange, California – sequence: 3 givenname: Vijay surname: Dhar fullname: Dhar, Vijay organization: Division of Neonatology, Children’s Hospital of Orange County, Orange, California – sequence: 4 givenname: John P. surname: Cleary fullname: Cleary, John P. organization: Division of Neonatology, Children’s Hospital of Orange County, Orange, California – sequence: 5 givenname: Sudeep surname: Kukreja fullname: Kukreja, Sudeep organization: Division of Neonatology, Children’s Hospital of Orange County, Orange, California – sequence: 6 givenname: Mindy surname: Morris fullname: Morris, Mindy organization: Division of Neonatology, Children’s Hospital of Orange County, Orange, California – sequence: 7 givenname: Ofelia M. surname: Vargas-Shiraishi fullname: Vargas-Shiraishi, Ofelia M. organization: Division of Pediatric Infectious Diseases, Children’s Hospital of Orange County, Orange, California – sequence: 8 givenname: Negar surname: Ashouri fullname: Ashouri, Negar organization: Division of Pediatric Infectious Diseases, Children’s Hospital of Orange County, Orange, California – sequence: 9 givenname: Jasjit surname: Singh fullname: Singh, Jasjit organization: Division of Pediatric Infectious Diseases, Children’s Hospital of Orange County, Orange, California |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22575730$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20206784$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl-L00AUxYOsuLvVr6ADIr40dSZpOs2CSi3-g4V9UMG3YTJzY6c7ycSZSWv9Tn5Hb2jdhYLQlwRufufMzZlzmZy1roUkecbohFE2e7WeKGvauAIvJxnFKc0mOH-QXLA5L1PGpt_PkgvKpmWalWx-nlyGsKaU5mWRPUrOM5rRGZ9PL5I_N62CdAtwa3fEms4F10hLZNOtXARvlGnJOyIDWcpWGy1J51232ln5ywSC3zbgUee2pDI-rsgWzI9VRAgaGXsPiNSyjeGKLAZl6EBFs4Ex8WjnGvMb9Ji4DtrUygrsmHRWKqhcqlwbvbMWNOmMdZGE2Ovd4-RhLW2AJ4f3KPn24f3X5af0-ubj5-XiOlVFXsaUV1LLolK8UjWvdF5ULKuU0jmf0rxQNUBZ5fO6nJYUOc1qxhnT1XzKZ1mdKZmPkpd7X9z5Zw8hisYEBdbKFlwfBM9zRmc5uo2S50fk2vW-xeUEo0jN8MmQenqg-qoBLTpvGul34t89IPDiAMigpK0xHmXCPZcVvOD5cBzfcwrDDB7qO4RRMTRDrMVdM8TQDEEzgXNUvj5SKhNlNEPO0tgT9Iu9HjD3jQEvgjKA5dHG46UK7cwJHm-OPAbO4A_fwg7CfXIioEB8Gfo71JdhczGnweDt_w1OWuEv5AMIcw |
| CitedBy_id | crossref_primary_10_1016_j_jddst_2018_10_003 crossref_primary_10_1002_14651858_CD003850_pub5 crossref_primary_10_1007_s40121_020_00382_7 crossref_primary_10_1016_j_ijpharm_2017_03_019 crossref_primary_10_1016_j_riam_2013_05_012 crossref_primary_10_12677_ACM_2021_115328 crossref_primary_10_3390_ph18030364 crossref_primary_10_1093_cid_ciz076 crossref_primary_10_5385_nm_2013_20_3_361 crossref_primary_10_1016_j_pepo_2012_05_001 crossref_primary_10_1111_j_1529_8019_2011_01399_x crossref_primary_10_1007_s12281_013_0167_5 crossref_primary_10_1016_j_riam_2013_06_002 crossref_primary_10_1128_CMR_00010_19 crossref_primary_10_1097_MOP_0b013e32835c1fc2 crossref_primary_10_1007_s12281_013_0134_1 crossref_primary_10_1093_cid_ciz091 |
| Cites_doi | 10.1097/INF.0b013e31819f1f50 10.1007/BF02768745 10.1542/peds.110.2.285 10.1097/00006454-199708000-00007 10.1542/peds.107.2.293 10.1038/clpt.1993.147 10.1002/pbc.21239 10.1097/INF.0b013e318170bb0c 10.1128/AAC.01305-05 10.1097/00006454-199802000-00013 10.1007/s004310050906 10.1097/01.inf.0000128777.22022.47 10.1542/peds.107.2.404 10.1097/00006454-199612000-00011 10.1128/AAC.01053-05 10.1542/peds.2005-2183 10.2165/00003495-200969030-00010 10.1016/j.jpeds.2005.03.036 10.1007/s150100070040 10.1016/j.jpeds.2005.04.016 10.1086/596757 10.1542/peds.2004-2227 10.1016/j.jpeds.2005.04.033 10.1016/j.jpeds.2005.02.020 10.1542/peds.73.2.153 10.1007/s10096-003-0993-4 10.1542/peds.2007-1130 10.1056/NEJMoa010494 10.1542/peds.2004-2292 10.1097/00006454-199811000-00010 10.1056/NEJMoa065733 |
| ContentType | Journal Article |
| Copyright | 2010 2015 INIST-CNRS Copyright 2010. Published by EM Inc USA. Copyright Elsevier Limited Feb 2010 |
| Copyright_xml | – notice: 2010 – notice: 2015 INIST-CNRS – notice: Copyright 2010. Published by EM Inc USA. – notice: Copyright Elsevier Limited Feb 2010 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88C 88E 8AO 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M1P M2O M7N MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.1016/j.clinthera.2010.02.016 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Nursing & Allied Health Source Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Healthcare Administration Database Medical Database ProQuest Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Research Library (Corporate) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Research Library Prep MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-114X |
| EndPage | 271 |
| ExternalDocumentID | 2734245441 20206784 22575730 10_1016_j_clinthera_2010_02_016 S0149291810000676 1_s2_0_S0149291810000676 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United States--US California |
| GeographicLocations_xml | – name: United States--US – name: California |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 29B 4.4 457 4G. 53G 5RE 5VS 6J9 6PF 7-5 71M 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8P~ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABUWG ABWVN ABXDB ABZDS ACDAQ ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EFLBG EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HMCUK HVGLF HZ~ H~9 IHE J1W KOM M0T M1P M2O M41 MO0 N9A NAPCQ O-L O9- OAUVE OD~ OGGZJ OO0 OZT P-8 P-9 PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO Q38 R2- ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSP SSZ SV3 T5K UHS UKHRP WH7 WOW XOL Z5R ZGI ZXP ~G- ~HD 0SF 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW NCXOZ RIG AAIAV AATCM ABLVK ABYKQ AJBFU LCYCR AAYXX CITATION PUEGO AGCQF AGRNS IQODW CGR CUY CVF ECM EIF NPM 7XB 8FK K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c539t-7bada5bc7bcf7bd35b12bccd374035cfee9b38f9490da5d1f1711db84762f2ca3 |
| IEDL.DBID | BENPR |
| ISSN | 0149-2918 1879-114X |
| IngestDate | Sun Sep 28 01:31:36 EDT 2025 Tue Oct 07 06:25:34 EDT 2025 Mon Jul 21 06:04:05 EDT 2025 Mon Jul 21 09:12:04 EDT 2025 Thu Oct 02 04:21:28 EDT 2025 Thu Apr 24 23:03:55 EDT 2025 Fri Feb 23 02:23:23 EST 2024 Sun Feb 23 10:18:55 EST 2025 Tue Oct 14 19:35:54 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | liposomal amphotericin B Candida prophylaxis neonates Premature Candidiasis Mycosis Pregnancy disorders Infant Fungi Very low birthweight Prospective Prevention Antiprotozoal agent Antifungal agent Randomization Weekly Fungi Imperfecti Human Liposome Infection Newborn diseases Antibiotic Newborn Prematurity Amphotericin B Polyenic compound Candida Placebo Parasiticide |
| Language | English |
| License | CC BY 4.0 Copyright 2010. Published by EM Inc USA. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c539t-7bada5bc7bcf7bd35b12bccd374035cfee9b38f9490da5d1f1711db84762f2ca3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Undefined-1 ObjectType-Feature-3 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 20206784 |
| PQID | 1033161031 |
| PQPubID | 1226358 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_733106340 proquest_journals_1033161031 pubmed_primary_20206784 pascalfrancis_primary_22575730 crossref_primary_10_1016_j_clinthera_2010_02_016 crossref_citationtrail_10_1016_j_clinthera_2010_02_016 elsevier_sciencedirect_doi_10_1016_j_clinthera_2010_02_016 elsevier_clinicalkeyesjournals_1_s2_0_S0149291810000676 elsevier_clinicalkey_doi_10_1016_j_clinthera_2010_02_016 |
| PublicationCentury | 2000 |
| PublicationDate | 2010-02-01 |
| PublicationDateYYYYMMDD | 2010-02-01 |
| PublicationDate_xml | – month: 02 year: 2010 text: 2010-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Bridgewater, NJ |
| PublicationPlace_xml | – name: Bridgewater, NJ – name: United States – name: Bridgewater |
| PublicationTitle | Clinical therapeutics |
| PublicationTitleAlternate | Clin Ther |
| PublicationYear | 2010 |
| Publisher | EM Inc USA Elsevier Elsevier Limited |
| Publisher_xml | – name: EM Inc USA – name: Elsevier – name: Elsevier Limited |
| References | Andes, Forrest, Lepak (bib29) 2006; 50 Kaufman, Boyle, Hazen (bib20) 2001; 345 Kaufman, Boyle, Hazen (bib22) 2005; 147 Manzoni, Leonessa, Galleto (bib26) 2008; 27 Ringdén, Andstrom, Remberger (bib11) 1997; 1 Scarcella, Pasquariello, Giugliano (bib6) 1998; 17 Tollermar, Ringdén, Andersson (bib10) 1993; 12 Manzoni, Stolfi, Pugni (bib25) 2007; 356 Moen, Lyseng-Williamson, Scott (bib5) 2009; 69 Benjamin, Stoll, Fanaroff (bib2) 2006; 117 Wenzl, Schefels, Hörnchen, Skopnik (bib17) 1998; 157 Baley, Kliegman, Fanaroff (bib3) 1984; 73 Stoll, Hansen, Fanaroff (bib1) 2002; 110 McGuire, Clerihew, Austin (bib34) 2004 Long, Stevenson (bib31) 2005; 147 Weitkamp, Poets, Sievers (bib7) 1998; 26 Neely, Schreiber (bib32) 2001; 107 Austin, Darlow (bib35) 2004 Roman, Osunkwo, Militano (bib12) 2008; 50 Driessen, Ellis, Cooper (bib15) 1996; 15 Saxén, Hoppu, Pohjavuori (bib16) 1993; 54 Manzoni, Arisio, Mostert (bib24) 2006; 117 Yoder, Sutton, Winter, Coalson (bib30) 2004; 23 Juster-Reicher, Leibovitz, Linder (bib8) 2000; 28 Huttova, Hartmanova, Kralinsky (bib13) 1998; 17 Healy, Campbell, Zaccaria, Baker (bib27) 2008; 121 Healy, Baker, Zaccaria, Campbell (bib21) 2005; 147 Bertini, Perugi, Dani (bib23) 2005; 147 Pappas, Kauffman, Andes (bib4) 2009; 48 Kicklighter, Springer, Cox (bib19) 2001; 107 Fanaroff (bib33) 2006; 117 Wade, Benjamin, Kaufman (bib18) 2009; 28 Juster-Reichter, Fidel-Rimon, Amitay (bib9) 2003; 22 Wainer, Cooper, Gouws, Akierman (bib14) 1997; 16 Andes, Lepak, Nett (bib28) 2006; 50 Stoll (10.1016/j.clinthera.2010.02.016_bib1) 2002; 110 Driessen (10.1016/j.clinthera.2010.02.016_bib15) 1996; 15 Kicklighter (10.1016/j.clinthera.2010.02.016_bib19) 2001; 107 Neely (10.1016/j.clinthera.2010.02.016_bib32) 2001; 107 Austin (10.1016/j.clinthera.2010.02.016_bib35) 2004 Juster-Reichter (10.1016/j.clinthera.2010.02.016_bib9) 2003; 22 Manzoni (10.1016/j.clinthera.2010.02.016_bib26) 2008; 27 Baley (10.1016/j.clinthera.2010.02.016_bib3) 1984; 73 Juster-Reicher (10.1016/j.clinthera.2010.02.016_bib8) 2000; 28 Andes (10.1016/j.clinthera.2010.02.016_bib28) 2006; 50 Wenzl (10.1016/j.clinthera.2010.02.016_bib17) 1998; 157 McGuire (10.1016/j.clinthera.2010.02.016_bib34) 2004 Moen (10.1016/j.clinthera.2010.02.016_bib5) 2009; 69 Pappas (10.1016/j.clinthera.2010.02.016_bib4) 2009; 48 Weitkamp (10.1016/j.clinthera.2010.02.016_bib7) 1998; 26 Wade (10.1016/j.clinthera.2010.02.016_bib18) 2009; 28 Roman (10.1016/j.clinthera.2010.02.016_bib12) 2008; 50 Healy (10.1016/j.clinthera.2010.02.016_bib21) 2005; 147 Ringdén (10.1016/j.clinthera.2010.02.016_bib11) 1997; 1 Manzoni (10.1016/j.clinthera.2010.02.016_bib25) 2007; 356 Healy (10.1016/j.clinthera.2010.02.016_bib27) 2008; 121 Kaufman (10.1016/j.clinthera.2010.02.016_bib20) 2001; 345 Tollermar (10.1016/j.clinthera.2010.02.016_bib10) 1993; 12 Manzoni (10.1016/j.clinthera.2010.02.016_bib24) 2006; 117 Kaufman (10.1016/j.clinthera.2010.02.016_bib22) 2005; 147 Andes (10.1016/j.clinthera.2010.02.016_bib29) 2006; 50 Saxén (10.1016/j.clinthera.2010.02.016_bib16) 1993; 54 Wainer (10.1016/j.clinthera.2010.02.016_bib14) 1997; 16 Long (10.1016/j.clinthera.2010.02.016_bib31) 2005; 147 Scarcella (10.1016/j.clinthera.2010.02.016_bib6) 1998; 17 Benjamin (10.1016/j.clinthera.2010.02.016_bib2) 2006; 117 Huttova (10.1016/j.clinthera.2010.02.016_bib13) 1998; 17 Fanaroff (10.1016/j.clinthera.2010.02.016_bib33) 2006; 117 Yoder (10.1016/j.clinthera.2010.02.016_bib30) 2004; 23 Bertini (10.1016/j.clinthera.2010.02.016_bib23) 2005; 147 |
| References_xml | – volume: 26 start-page: 11 year: 1998 end-page: 15 ident: bib7 publication-title: Infection. – volume: 147 start-page: 172 year: 2005 end-page: 179 ident: bib22 article-title: Twice weekly fluconazole prophylaxis for prevention of invasive publication-title: J Pediatr. – volume: 1 start-page: 124 year: 1997 end-page: 129 ident: bib11 article-title: Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation publication-title: Pediatr Transplant. – volume: 110 start-page: 285 year: 2002 end-page: 291 ident: bib1 article-title: Late-onset sepsis in very low birth weight neonates: The experience of the NICHD Neonatal Research Network publication-title: Pediatrics. – volume: 107 start-page: 293 year: 2001 end-page: 298 ident: bib19 article-title: Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant publication-title: Pediatrics. – volume: 15 start-page: 1107 year: 1996 end-page: 1112 ident: bib15 article-title: Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: A prospective randomized trial publication-title: Pediatr Infect Dis J. – volume: 73 start-page: 153 year: 1984 end-page: 157 ident: bib3 article-title: Disseminated fungal infections in very low-birth-weight infants: Therapeutic toxicity publication-title: Pediatrics. – volume: 50 start-page: 2374 year: 2006 end-page: 2383 ident: bib29 article-title: Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: Fluconazole and publication-title: Antimicrob Agents Chemother. – volume: 50 start-page: 2384 year: 2006 end-page: 2394 ident: bib28 article-title: In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible publication-title: Antimicrob Agents Chemother. – volume: 345 start-page: 1660 year: 2001 end-page: 1666 ident: bib20 article-title: Fluconazole prophylaxis against fungal colonization and infection in pre-term infants publication-title: N Engl J Med. – volume: 117 start-page: 84 year: 2006 end-page: 92 ident: bib2 article-title: Neonatal candidiasis among extremely low birth weight infants: Risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months publication-title: Pediatrics. – volume: 16 start-page: 763 year: 1997 end-page: 767 ident: bib14 article-title: Prospective study of fluconazole therapy in systemic neonatal fungal infection publication-title: Pediatr Infect Dis J. – volume: 147 start-page: 135 year: 2005 end-page: 141 ident: bib31 article-title: Reducing publication-title: J Pediatr. – volume: 157 start-page: 661 year: 1998 end-page: 662 ident: bib17 article-title: Pharmacokinetics of oral fluconazole in premature infants publication-title: Eur J Pediatr. – volume: 28 start-page: 717 year: 2009 end-page: 723 ident: bib18 article-title: Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants publication-title: Pediatr Infect Dis J. – volume: 17 start-page: 146 year: 1998 end-page: 148 ident: bib6 article-title: Liposomal amphotericin B treatment for neonatal fungal infections publication-title: Pediatr Infect DisJ. – volume: 107 start-page: 404 year: 2001 end-page: 405 ident: bib32 article-title: Fluconazole prophylaxis in the very low birth weight infant: Not ready for prime time publication-title: Pediatrics. – volume: 12 start-page: 557 year: 1993 end-page: 582 ident: bib10 article-title: Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients publication-title: Bone Marrow Transplant. – volume: 48 start-page: 503 year: 2009 end-page: 535 ident: bib4 article-title: Clinical practice guidelines for the management of candidasis: 2009 Update by the Infectious Diseases Society of America publication-title: Clin Infect Dis. – volume: 17 start-page: 1012 year: 1998 end-page: 1015 ident: bib13 publication-title: Pediatr Infect Dis J. – volume: 356 start-page: 2483 year: 2007 end-page: 2495 ident: bib25 article-title: A multicenter, randomized trial of prophylactic fluconazole in preterm neonates publication-title: N Engl J Med. – start-page: CD003850 year: 2004 ident: bib34 article-title: Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants publication-title: Cochrane Database Syst Rev. – volume: 23 start-page: 687 year: 2004 end-page: 688 ident: bib30 article-title: Resistant publication-title: Pediatr Infect Dis J. – volume: 50 start-page: 325 year: 2008 end-page: 330 ident: bib12 article-title: Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation publication-title: Pediatr Blood Cancer. – volume: 117 start-page: 214 year: 2006 end-page: 215 ident: bib33 article-title: Fluconazole for the prevention of fungal infections: Get ready, get set, caution publication-title: Pediatrics. – volume: 27 start-page: 731 year: 2008 end-page: 737 ident: bib26 article-title: Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant publication-title: Pediatr Infect Dis J. – start-page: CD003478 year: 2004 ident: bib35 article-title: Prophylactic oral antifungal agents to prevent systemic publication-title: Cochrane Database Syst Rev. – volume: 28 start-page: 223 year: 2000 end-page: 226 ident: bib8 article-title: Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants publication-title: Infection. – volume: 54 start-page: 269 year: 1993 end-page: 277 ident: bib16 article-title: Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life publication-title: Clin Pharmacol Ther. – volume: 22 start-page: 603 year: 2003 end-page: 607 ident: bib9 article-title: Highdose liposomal amphotericin B in the therapy of systemic candidiasis in neonates publication-title: Eur J Clin Microbiol Infect Dis. – volume: 121 start-page: 703 year: 2008 end-page: 710 ident: bib27 article-title: Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant publication-title: Pediatrics. – volume: 147 start-page: 166 year: 2005 end-page: 171 ident: bib21 article-title: Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit publication-title: J Pediatr. – volume: 147 start-page: 162 year: 2005 end-page: 165 ident: bib23 article-title: Fluconazole prophylaxis prevents invasive fungal infection in highrisk, very low birth weight infants publication-title: J Pediatr. – volume: 69 start-page: 361 year: 2009 end-page: 392 ident: bib5 article-title: Liposomal amphotericin B: A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections publication-title: Drugs. – volume: 117 start-page: e22 year: 2006 end-page: e32 ident: bib24 article-title: Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: A single-center, 6-year, retrospective cohort study publication-title: Pediatrics. – volume: 28 start-page: 717 year: 2009 ident: 10.1016/j.clinthera.2010.02.016_bib18 article-title: Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants publication-title: Pediatr Infect Dis J. doi: 10.1097/INF.0b013e31819f1f50 – volume: 26 start-page: 11 year: 1998 ident: 10.1016/j.clinthera.2010.02.016_bib7 article-title: Candida infection in very low birth-weight infants: Outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome) publication-title: Infection. doi: 10.1007/BF02768745 – volume: 110 start-page: 285 year: 2002 ident: 10.1016/j.clinthera.2010.02.016_bib1 article-title: Late-onset sepsis in very low birth weight neonates: The experience of the NICHD Neonatal Research Network publication-title: Pediatrics. doi: 10.1542/peds.110.2.285 – volume: 16 start-page: 763 year: 1997 ident: 10.1016/j.clinthera.2010.02.016_bib14 article-title: Prospective study of fluconazole therapy in systemic neonatal fungal infection publication-title: Pediatr Infect Dis J. doi: 10.1097/00006454-199708000-00007 – volume: 107 start-page: 293 year: 2001 ident: 10.1016/j.clinthera.2010.02.016_bib19 article-title: Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant publication-title: Pediatrics. doi: 10.1542/peds.107.2.293 – volume: 54 start-page: 269 year: 1993 ident: 10.1016/j.clinthera.2010.02.016_bib16 article-title: Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life publication-title: Clin Pharmacol Ther. doi: 10.1038/clpt.1993.147 – volume: 50 start-page: 325 year: 2008 ident: 10.1016/j.clinthera.2010.02.016_bib12 article-title: Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation publication-title: Pediatr Blood Cancer. doi: 10.1002/pbc.21239 – volume: 1 start-page: 124 year: 1997 ident: 10.1016/j.clinthera.2010.02.016_bib11 article-title: Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation publication-title: Pediatr Transplant. – volume: 27 start-page: 731 year: 2008 ident: 10.1016/j.clinthera.2010.02.016_bib26 article-title: Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies publication-title: Pediatr Infect Dis J. doi: 10.1097/INF.0b013e318170bb0c – start-page: CD003478 year: 2004 ident: 10.1016/j.clinthera.2010.02.016_bib35 article-title: Prophylactic oral antifungal agents to prevent systemic Candida infection in preterm infants publication-title: Cochrane Database Syst Rev. – volume: 50 start-page: 2384 year: 2006 ident: 10.1016/j.clinthera.2010.02.016_bib28 article-title: In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.01305-05 – volume: 17 start-page: 146 year: 1998 ident: 10.1016/j.clinthera.2010.02.016_bib6 article-title: Liposomal amphotericin B treatment for neonatal fungal infections publication-title: Pediatr Infect DisJ. doi: 10.1097/00006454-199802000-00013 – volume: 157 start-page: 661 year: 1998 ident: 10.1016/j.clinthera.2010.02.016_bib17 article-title: Pharmacokinetics of oral fluconazole in premature infants publication-title: Eur J Pediatr. doi: 10.1007/s004310050906 – volume: 23 start-page: 687 year: 2004 ident: 10.1016/j.clinthera.2010.02.016_bib30 article-title: Resistant Candida parapsilosis associated with long term fluconazole prophylaxis in an animal model publication-title: Pediatr Infect Dis J. doi: 10.1097/01.inf.0000128777.22022.47 – volume: 107 start-page: 404 year: 2001 ident: 10.1016/j.clinthera.2010.02.016_bib32 article-title: Fluconazole prophylaxis in the very low birth weight infant: Not ready for prime time publication-title: Pediatrics. doi: 10.1542/peds.107.2.404 – start-page: CD003850 issue: 1 year: 2004 ident: 10.1016/j.clinthera.2010.02.016_bib34 article-title: Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants publication-title: Cochrane Database Syst Rev. – volume: 15 start-page: 1107 year: 1996 ident: 10.1016/j.clinthera.2010.02.016_bib15 article-title: Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: A prospective randomized trial publication-title: Pediatr Infect Dis J. doi: 10.1097/00006454-199612000-00011 – volume: 50 start-page: 2374 year: 2006 ident: 10.1016/j.clinthera.2010.02.016_bib29 article-title: Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: Fluconazole and Candida albicans publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.01053-05 – volume: 117 start-page: 214 year: 2006 ident: 10.1016/j.clinthera.2010.02.016_bib33 article-title: Fluconazole for the prevention of fungal infections: Get ready, get set, caution publication-title: Pediatrics. doi: 10.1542/peds.2005-2183 – volume: 69 start-page: 361 year: 2009 ident: 10.1016/j.clinthera.2010.02.016_bib5 article-title: Liposomal amphotericin B: A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections publication-title: Drugs. doi: 10.2165/00003495-200969030-00010 – volume: 147 start-page: 172 year: 2005 ident: 10.1016/j.clinthera.2010.02.016_bib22 article-title: Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight publication-title: J Pediatr. doi: 10.1016/j.jpeds.2005.03.036 – volume: 28 start-page: 223 year: 2000 ident: 10.1016/j.clinthera.2010.02.016_bib8 article-title: Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants publication-title: Infection. doi: 10.1007/s150100070040 – volume: 147 start-page: 166 year: 2005 ident: 10.1016/j.clinthera.2010.02.016_bib21 article-title: Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit publication-title: J Pediatr. doi: 10.1016/j.jpeds.2005.04.016 – volume: 48 start-page: 503 year: 2009 ident: 10.1016/j.clinthera.2010.02.016_bib4 article-title: Clinical practice guidelines for the management of candidasis: 2009 Update by the Infectious Diseases Society of America publication-title: Clin Infect Dis. doi: 10.1086/596757 – volume: 117 start-page: e22 year: 2006 ident: 10.1016/j.clinthera.2010.02.016_bib24 article-title: Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: A single-center, 6-year, retrospective cohort study publication-title: Pediatrics. doi: 10.1542/peds.2004-2227 – volume: 147 start-page: 135 year: 2005 ident: 10.1016/j.clinthera.2010.02.016_bib31 article-title: Reducing Candida infections during neonatal intensive care: Management choices, infection control, and fluconazole prophylaxis publication-title: J Pediatr. doi: 10.1016/j.jpeds.2005.04.033 – volume: 147 start-page: 162 year: 2005 ident: 10.1016/j.clinthera.2010.02.016_bib23 article-title: Fluconazole prophylaxis prevents invasive fungal infection in highrisk, very low birth weight infants publication-title: J Pediatr. doi: 10.1016/j.jpeds.2005.02.020 – volume: 12 start-page: 557 year: 1993 ident: 10.1016/j.clinthera.2010.02.016_bib10 article-title: Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients publication-title: Bone Marrow Transplant. – volume: 73 start-page: 153 year: 1984 ident: 10.1016/j.clinthera.2010.02.016_bib3 article-title: Disseminated fungal infections in very low-birth-weight infants: Therapeutic toxicity publication-title: Pediatrics. doi: 10.1542/peds.73.2.153 – volume: 22 start-page: 603 year: 2003 ident: 10.1016/j.clinthera.2010.02.016_bib9 article-title: Highdose liposomal amphotericin B in the therapy of systemic candidiasis in neonates publication-title: Eur J Clin Microbiol Infect Dis. doi: 10.1007/s10096-003-0993-4 – volume: 121 start-page: 703 year: 2008 ident: 10.1016/j.clinthera.2010.02.016_bib27 article-title: Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species publication-title: Pediatrics. doi: 10.1542/peds.2007-1130 – volume: 345 start-page: 1660 year: 2001 ident: 10.1016/j.clinthera.2010.02.016_bib20 article-title: Fluconazole prophylaxis against fungal colonization and infection in pre-term infants publication-title: N Engl J Med. doi: 10.1056/NEJMoa010494 – volume: 117 start-page: 84 year: 2006 ident: 10.1016/j.clinthera.2010.02.016_bib2 article-title: Neonatal candidiasis among extremely low birth weight infants: Risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months publication-title: Pediatrics. doi: 10.1542/peds.2004-2292 – volume: 17 start-page: 1012 year: 1998 ident: 10.1016/j.clinthera.2010.02.016_bib13 article-title: Candida fungemia in neonates treated with fluconazole: Report of forty cases, including eight with meningitis publication-title: Pediatr Infect Dis J. doi: 10.1097/00006454-199811000-00010 – volume: 356 start-page: 2483 year: 2007 ident: 10.1016/j.clinthera.2010.02.016_bib25 article-title: A multicenter, randomized trial of prophylactic fluconazole in preterm neonates publication-title: N Engl J Med. doi: 10.1056/NEJMoa065733 |
| SSID | ssj0003952 |
| Score | 2.0404654 |
| Snippet | Objective: This study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for
Candida prophylaxis in very low birth weight (VLBW) neonates.... Abstract Objective: This study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for Candida prophylaxis in very low birth weight (VLBW)... This study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for Candida prophylaxis in very low birth weight (VLBW) neonates. This... Objective_ This study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for Candida prophylaxis in very low birth weight (VLBW) neonates.... This study was conducted to evaluate once-weekly liposomal amphotericin B (L-AmB) for Candida prophylaxis in very low birth weight (VLBW)... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 265 |
| SubjectTerms | Amphotericin B - administration & dosage Amphotericin B - adverse effects Antifungal agents Antifungal Agents - administration & dosage Antifungal Agents - adverse effects Biological and medical sciences Birth weight Bone marrow Candida prophylaxis Candidiasis - diagnosis Candidiasis - etiology Candidiasis - prevention & control Children & youth Disease prevention Diseases of mother, fetus and pregnancy Drug Administration Schedule Female Fungal infections Gestational Age Gynecology. Andrology. Obstetrics Humans Infant, Newborn Infant, Premature Infant, Very Low Birth Weight Infectious diseases Intensive care Internal Medicine liposomal amphotericin B Male Medical Education Medical sciences Mortality neonates Pediatrics Pharmacokinetics Pharmacology. Drug treatments Pilot Projects Pregnancy. Fetus. Placenta Premature babies Premature birth Prospective Studies Stem cell transplantation Treatment Outcome |
| SummonAdditionalLinks | – databaseName: ScienceDirect Freedom Collection Journals dbid: AIKHN link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb5swELa6VJomTdPW_aLrKj9MfYIFMMbQtyxalW1q14dW6ptlG6My0RAForT7n_Y_7gyGKFqnTtor3DnGd_7OhO_uEPog41DJSKcepaaoNoEznBDM92hMhE4JZb40ucOnZ_HsMvp6Ra920LTPhTG0Sov9Haa3aG2vjO1qjhdFMTa0JIjtEKE6zI0foV2IP0kyQruTL99mZwMgk7RtvGPkPaOwRfMyCYhtqpOleYUffdP7_P4g9XQhali6vOt58fdDaRucTp6jZ_ZUiSfdxF-gHT3fQ49P7XfzPXR03lWovnPxxSbhqnbxET7f1K6-e4l-fYcF8NZtmX1cFouqrm5gYAE2r0xVZxgOf8KixlOTDpMJDFMDQ5Xitqgx3IONAXrVGsti2VzjdfvHKwiZyrCrpQaR3BBvjvHEaPZpni6GR82qm-KnzlxsGnp54Jy6dHFLGZOVZxn1pc7woiirBrdlcV-hy5PPF9OZZzs6eIqStPGYFJmgUjGpciYzQmUQSqUywiKfUJVrnUqS5GmU-iCXBXnAgiCTEEHjMA-VIK_RaF7N9VuEMxYzEYsgCmUeQVAVyidEJ6FKkxCghDko7k3IlS13brpulLzntf3gg-25sT33Qw7XHeQPiouu4sfDKknvI7xPaAUI5hCVHlZl96nq2kJJzQNegyT_w90ddDxobu2Yf_vZwy1XHp4U4J1RQH0HHfS-zTdTgSWGNwSIAw7Cw23AI_ORScx1taq56QEKx94IRnjTbYnN2L7pFZBE-_8z83foSUfgMIyiAzRqliv9Hs6FjTy0-_43Y8dlrw priority: 102 providerName: Elsevier |
| Title | Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: A prospective, randomized, open-label, placebo-controlled pilot study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0149291810000676 https://www.clinicalkey.es/playcontent/1-s2.0-S0149291810000676 https://dx.doi.org/10.1016/j.clinthera.2010.02.016 https://www.ncbi.nlm.nih.gov/pubmed/20206784 https://www.proquest.com/docview/1033161031 https://www.proquest.com/docview/733106340 |
| Volume | 32 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect (Elsevier) customDbUrl: eissn: 1879-114X dateEnd: 20131231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect (Elsevier) customDbUrl: eissn: 1879-114X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection 2025 customDbUrl: eissn: 1879-114X dateEnd: 20131231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1879-114X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: AKRWK dateStart: 19950101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1879-114X dateEnd: 20250903 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1879-114X dateEnd: 20250903 omitProxy: true ssIdentifier: ssj0003952 issn: 0149-2918 databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9tAEF4SG0qhlDZ9uU3NHkpOVpC0klYKlOKEBLclrikJ-LbsS8RFsVzLxk0P_Uf9j53RywTSphcfpJ21pJmdGWlnvo-QdyrytQps4oQhgmozyOGk5K4TRkzahIXcVdg7fD6ORpfBp2k43SHjphcGyyobn1g6apNr_EYOq5sxyE7ABj8svjvIGoW7qw2FhqypFcz7EmJsl3R9RMbqkO7x6XjytfXNLCk5ePC9wPETL75V8YW9iGXXU13x5R-6SIN-d7x6tJAFPMW0or_4e35axqmzJ-RxnWDSYWURT8mOne-RB-f1FvoeOZhUYNU3A3qx7b0qBvSATrYw1jfPyO8vYA_OpkTcp9lskRf5NUwsQf05AjzDdPSYyoKeYGeMkRQuDXSWyR-zgsI5WCMgl2-omi1XV3RTfoOFQQgSu15aGJJiDc4RHaJk0_E5oHCrJr-e_bRmQJHbywE7tdmAltVjKnfq4vrMGrqYZfmKlgi5z8nl2enFycipyR0cHbJk5XAljQyV5kqnXBkWKs9XWhvGA5eFOrU2USxOkyBxYZzxUo97nlEQTCM_9bVkL0hnns_tK0INj7iMpBf4Kg0gvkoNtmJjXyexD16F90jUqFDoGvkcCTgy0ZS4fROt7gXqXri-gOM94raCiwr8436RuLER0fS2gjcWEKDuF-V3idqi9iqF8EQBI8uCvASt16uyDZA8aiXrxKlKiP7vb_u3TLm9U_D0PIQA0CP7jW2L7aW0y7FHaHsaXBPuN8m5zdeFQDpQyIADmOFltSS2c7tIGxAHr_899xvysKrWwPKhfdJZLdf2LSSBK9Unu4e_PPjlU94n3eHHz6Nxv17tfwB5h2M9 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VVgIkhKC8AqXsAXqKK3vX9tqVKtSWViltQoRSqbdlX1ZTuXGIE4Xwn_gL_DZm_YoqFcqlV3tnbGue652ZD6H3MiRK-iZ2gsAO1aaQwwnBXCcIqTAxDZgrbe9wtxd2zvzP58H5Cvpd98LYssraJxaOWmfK_iMH66YUshPQwY_j745FjbKnqzWEhqigFfRuMWKsauw4MYs5bOHy3eNPIO8PhBwdDg46ToUy4KiAxlOHSaFFIBWTKmFS00B6RCqlKfNdGqjEmFjSKIn92IV12ks85nlaglcPSUKUoMD3HlrzqR_D5m9t_7DX_9rEAhoXmD92H-KQ2IuuVZjZ3seiy6qqMCPbroVdvzk-PhqLHKSWlHAbf8-Hi7h49AQ9rhJavFdq4FO0Ykbr6H63OrJfR1v9cjj2oo0Hy16vvI23cH85NnvxDP36AvrnzIsJ_zgdjrM8uwLGAtQtswOlgR3exyLHB7YTRwsMrwY6koofwxzDPbBJoMvmWA4n0ws8L_75wiI7lHY2MbAksTU_O3jPUtYdpm0Mn6qzq-FPo9vYYok5YBcmbeOiWk1mTlXMnxqNx8M0m-JiIu9zdHYnYn6BVkfZyLxCWLOQiVB4PpGJD_FcKNBNExEVRwS8GGuhsBYhV9WkdQv4kfK6pO6SN7LnVvbcJRyut5DbEI7LYSO3k0S1jvC6lxa8P4eAeDspu4nU5JUXy7nHc1hZFADGVnu9MrsByp2GskrUygTs_x67eU2Vmy-FyMICCDgttFHrNl--SmP-LYSb2-AK7fmWGJlslnMLPwoZtw8cXpYmseTtWpiCyH_9b97v0IPOoHvKT497J2_Qw7JSxJYubaDV6WRm3kICOpWblZVj9O2uHcsf9L2fGA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIlVICEF5BUrZA_QUg71re72VECotUUtpyaGVctvuy2oqNw5xohD-E3-AX8esX1GlQrn0au-Mbc3Tu9_MIPRGxUSr0HIvilxTbQo5nJTM96KYSstpxHzlaoePjuP90_DLIBqsoN9NLYyDVTY-sXTUJtdujxysm1LITkAH36c1LKK_1_s4_u65CVLupLUZp1GpyKFdzOH3rfhwsAeyfktI7_PJ7r5XTxjwdET51GNKGhkpzZROmTI0UgFRWhvKQp9GOrWWK5qkPOQ-rDNBGrAgMAo8ekxSoiUFvnfQXUYpd3BCNmh_9ny4Qir4JPcID5Ir2DJX9VjWV9XYMvLOdwPXr4-M98eyAHml1aCNv2fCZUTsPUQP6lQW71S69wit2NE6WjuqD-vX0Va_aou96OKTZZVX0cVbuL9smL14jH59A83z5mVvf5wNx3mRXwJjCYqWu1bSwA5_wrLAu64Gx0gMrwbakckfwwLDPbBGoMvnWA0n03M8L3d7YZFrRzubWFiSOrTPNt5xlE1taRfDp5r8cvjTmi52U8Q8sAibdXGJU1O5V8P4M2vweJjlU1z24n2CTm9FyE_R6igf2ecIGxYzGcsgJCoNIZJLDVppE6J5QsB_sQ6KGxEKXfdYd6M-MtGA6S5EK3vhZC98IuB6B_kt4bhqM3IzSdLoiGiqaMHvCwiFN5Oy60htUfuvQgSigJUl9I877Q2qvAYot1vKOkWrUq__e-zmFVVuvxRiCosg1HTQRqPbYvkqreF3EG5vgxN0J1tyZPNZIdzgUci1Q-DwrDKJJW_fDShIwhf_5v0arYE7EV8Pjg9fonsVRMRhljbQ6nQys68g85yqzdLEMTq7bZ_yB7WonLI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Once-weekly+liposomal+amphotericin+B+as+Candida+prophylaxis+in+very+low+birth+weight+premature+infants%3A+A+prospective%2C+randomized%2C+open-label%2C+placebo-controlled+pilot+study&rft.jtitle=Clinical+therapeutics&rft.au=Arrieta%2C+Antonio+C.%2C+MD&rft.au=Shea%2C+Kathy%2C+BA&rft.au=Dhar%2C+Vijay%2C+MD&rft.au=Cleary%2C+John+P.%2C+MD&rft.date=2010-02-01&rft.issn=0149-2918&rft.volume=32&rft.issue=2&rft.spage=265&rft.epage=271&rft_id=info:doi/10.1016%2Fj.clinthera.2010.02.016&rft.externalDBID=ECK1-s2.0-S0149291810000676&rft.externalDocID=1_s2_0_S0149291810000676 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01492918%2FS0149291810X00042%2Fcov150h.gif |